Starling Oncology, Inc.
For the period ended Sep 30, 2026. Filed Nov 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended September 30, 2026, the following directors and officers of the Company adopted trading plans for the sales of shares of our common stock, as indicated below. Each trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
| Name and Title | Date of Adoption | Aggregate Number of Shares of Common Stock to Be Sold | Expiration Date of Rule 10b5-1 Trading Plan |
|---|---|---|---|
| Karen Johnson, Director | September 10, 2026 | Up to 33,600 | December 31, 2027 |
| Mark Pacala, Director | August 18, 2026 | Up to 148,000 | September 1, 2027 |
| Daniel Virnich, Chief Executive Officer | August 12, 2026 | Up to 350,000 | September 1, 2027 |
| Robert Carter, Chief Financial Officer | September 14, 2026 | Up to 108,455 | October 1, 2027 |
In our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, we inadvertently omitted disclosure about our director, Bradley Hively, adopting a Rule 10b5-1 Plan on May 22, 2026, with an expiration date of December 31, 2027, providing for the sale of up to an aggregate amount of 298,853 shares of common stock. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.